Ethan A Poweleit1, Stacey L Aldrich2, Lisa J Martin2,3, David Hahn4, Jeffrey R Strawn5,6, Laura B Ramsey1,2,4. 1. 1 Division of Research in Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 2. 2 Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio. 3. 3 Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 4. 4 Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 5. 5 Anxiety Disorders Research Program, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, Ohio. 6. 6 Division of Child and Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Abstract
Objective: To determine whether genetic variants in a pharmacokinetic gene (the number of CYP2C19 reduced function alleles [RFAs]), and in pharmacodynamic genes (HTR2A, SLC6A4, and GRIK4) influence sertraline tolerability and response in a cohort of pediatric patients with anxiety and depressive disorders. Methods: A retrospective analysis was performed using the electronic medical record data of 352 patients <19 years of age being treated for anxiety and/or depressive disorders with sertraline and who underwent routine clinical CYP2C19 genotyping. Additional genotyping and analysis of variants in HTR2A, SLC6A4, and GRIK4 were conducted for 249 patients. Multivariate regression models testing for associations with CYP2C19 were adjusted for concomitant use of interacting medications. Combinatorial classification and regression tree (CART) analyses containing all pharmacokinetic and pharmacodynamic genes and clinical factors were performed. Results: The maximum sertraline dose during the initial titration period of sertraline was inversely associated with the number of CYP2C19 RFAs and sertraline dose at 60 (p = 0.025) and 90 days (p = 0.025). HTR2A rs6313 was associated with sertraline dose (p = 0.011) and time to the average maximum sertraline dose (p = 0.039). Regarding efficacy, the number of CYP2C19 RFAs was not associated with the sertraline dose at the time of response (p = 0.22), whereas for the pharmacodynamic genes, only HTR2A rs6313 was associated with response dose (p = 0.022). An association was observed between predicted expression levels of SLC6A4 and the duration on sertraline (p = 0.025). Combinatorial CART and multivariate regression analyses implicated that pharmacodynamic genes and clinical factors influence the maximum sertraline dose and response dose. The total number of side effects was not associated with any of the variants tested. Conclusion: Both pharmacokinetic and pharmacodynamic factors, in addition to clinical and demographic components, influence sertraline dose, response, and tolerability, thereby necessitating further research to assess for the validity of these pharmacogenetic associations in children and adolescents.
Objective: To determine whether genetic variants in a pharmacokinetic gene (the number of CYP2C19 reduced function alleles [RFAs]), and in pharmacodynamic genes (HTR2A, SLC6A4, and GRIK4) influence sertraline tolerability and response in a cohort of pediatric patients with anxiety and depressive disorders. Methods: A retrospective analysis was performed using the electronic medical record data of 352 patients <19 years of age being treated for anxiety and/or depressive disorders with sertraline and who underwent routine clinical CYP2C19 genotyping. Additional genotyping and analysis of variants in HTR2A, SLC6A4, and GRIK4 were conducted for 249 patients. Multivariate regression models testing for associations with CYP2C19 were adjusted for concomitant use of interacting medications. Combinatorial classification and regression tree (CART) analyses containing all pharmacokinetic and pharmacodynamic genes and clinical factors were performed. Results: The maximum sertraline dose during the initial titration period of sertraline was inversely associated with the number of CYP2C19 RFAs and sertraline dose at 60 (p = 0.025) and 90 days (p = 0.025). HTR2Ars6313 was associated with sertraline dose (p = 0.011) and time to the average maximum sertraline dose (p = 0.039). Regarding efficacy, the number of CYP2C19 RFAs was not associated with the sertraline dose at the time of response (p = 0.22), whereas for the pharmacodynamic genes, only HTR2Ars6313 was associated with response dose (p = 0.022). An association was observed between predicted expression levels of SLC6A4 and the duration on sertraline (p = 0.025). Combinatorial CART and multivariate regression analyses implicated that pharmacodynamic genes and clinical factors influence the maximum sertraline dose and response dose. The total number of side effects was not associated with any of the variants tested. Conclusion: Both pharmacokinetic and pharmacodynamic factors, in addition to clinical and demographic components, influence sertraline dose, response, and tolerability, thereby necessitating further research to assess for the validity of these pharmacogenetic associations in children and adolescents.
Authors: Lisa B Namerow; Laura B Ramsey; Salma Malik; Samuele Cortese; Jeffrey R Strawn Journal: J Am Acad Child Adolesc Psychiatry Date: 2021-11-10 Impact factor: 8.829
Authors: Carl Y Zhang; Jennifer L Vande Voort; Deniz Yuruk; Jeffrey A Mills; Graham J Emslie; Betsy D Kennard; Taryn Mayes; Madhukar Trivedi; William V Bobo; Jeffrey R Strawn; Arjun P Athreya; Paul E Croarkin Journal: J Child Adolesc Psychopharmacol Date: 2022-06 Impact factor: 3.031
Authors: Rachel Huddart; J Kevin Hicks; Laura B Ramsey; Jeffrey R Strawn; D Max Smith; Margarita Bobonis Babilonia; Russ B Altman; Teri E Klein Journal: Pharmacogenet Genomics Date: 2020-02 Impact factor: 2.000
Authors: Lu Lu; Jeffrey A Mills; Hailong Li; Heidi K Schroeder; Sarah A Mossman; Sara T Varney; Kim M Cecil; Xiaoqi Huang; Qiyong Gong; Laura B Ramsey; Melissa P DelBello; John A Sweeney; Jeffrey R Strawn Journal: J Am Acad Child Adolesc Psychiatry Date: 2021-02-04 Impact factor: 13.113
Authors: Jeffrey R Strawn; Ethan A Poweleit; Chakradhara Rao S Uppugunduri; Laura B Ramsey Journal: Front Pharmacol Date: 2021-10-01 Impact factor: 5.810
Authors: Jennifer L Vande Voort; Scott S Orth; Julia Shekunov; Magdalena Romanowicz; Jennifer R Geske; Jessica A Ward; Nicole I Leibman; Mark A Frye; Paul E Croarkin Journal: J Am Acad Child Adolesc Psychiatry Date: 2021-06-05 Impact factor: 13.113